
Learn more about our latest update in #hematology here: go.merck.com/~upd
✓We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: merck.us/3TKXNuZ

Learn more about our latest update in #hematology here: go.merck.com/~upd

Today, we announced a positive CHMP opinion recommending the approval of an option to help protect against respiratory syncytial virus (#RSV) in certain at-risk children up to 24 months of age. Learn more: go.merck.com/~5sp

Today, we announced a positive CHMP opinion for a potential new combination treatment for certain people with #KidneyCancer in the European Union. Read more: go.merck.com/~aa0


Today we announced the initiation of a phase 3 study for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients with a history of them. Learn more about the trial: go.merck.com/~n3w




Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more: go.merck.com/~82i

Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO. go.merck.com/~5wh

We announced positive Phase 3 data for our investigational individualized neoantigen therapy in combination with our company’s immunotherapy for patients with completely resected stage IIB-IV #melanoma in collaboration with @moderna_tx. Read more: go.merck.com/~km1

Today, the European Commission approved a combination regimen for adults with muscle-invasive #BladderCancer (MIBC). Learn more about how we're helping advance cancer care with Pfizer and Astellas: go.merck.com/~oa7

We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer types: go.merck.com/~yuc

Today at #AAO2026, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: go.merck.com/~4ba

Today we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.merck.com/~73c
